Published in Cancer Res on January 01, 2008
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3. J Natl Cancer Inst (2009) 1.65
Non-random integration of the HPV genome in cervical cancer. PLoS One (2012) 1.43
Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst (2012) 1.38
Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology (2009) 1.36
Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev (2012) 1.33
Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev (2009) 1.18
In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res (2010) 1.10
HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol (2011) 1.10
Human papillomavirus molecular biology and disease association. Rev Med Virol (2015) 1.09
Human papillomavirus-16 and -18 in penile carcinomas: DNA methylation, chromosomal recombination and genomic variation. Int J Cancer (2008) 1.05
Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation. PLoS One (2011) 1.04
HIV Infection Alters the Spectrum of HPV Subtypes Found in Cervical Smears and Carcinomas from Kenyan Women. Open Virol J (2013) 0.99
A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol (2015) 0.98
Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology (2013) 0.96
HPV genotyping and site of viral integration in cervical cancers in Indian women. PLoS One (2012) 0.95
Physical state & copy number of high risk human papillomavirus type 16 DNA in progression of cervical cancer. Indian J Med Res (2014) 0.93
Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. PLoS One (2012) 0.93
The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase. J Virol (2010) 0.93
Comparison of prevalence, viral load, physical status and expression of human papillomavirus-16, -18 and -58 in esophageal and cervical cancer: a case-control study. BMC Cancer (2010) 0.93
A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. Am J Cancer Res (2011) 0.91
Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil. BMC Cancer (2013) 0.89
Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage. BMC Cancer (2014) 0.89
Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS One (2014) 0.87
Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol (2014) 0.87
Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay. Am J Pathol (2010) 0.86
Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology. Oncotarget (2016) 0.85
Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. Int J Cancer (2015) 0.84
Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical cancer. J Clin Microbiol (2008) 0.83
Viral carcinogenesis: factors inducing DNA damage and virus integration. Cancers (Basel) (2014) 0.82
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLoS One (2015) 0.81
Human papillomavirus (HPV) genome status & cervical cancer outcome - A retrospective study. Indian J Med Res (2015) 0.81
The human papillomavirus E6 oncogene represses a cell adhesion pathway and disrupts focal adhesion through degradation of TAp63β upon transformation. PLoS Pathog (2011) 0.81
The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer. PLoS One (2014) 0.81
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
Correlation between ebv co-infection and HPV16 genome integrity in Tunisian cervical cancer patients. Braz J Microbiol (2012) 0.79
Cell-type specific transcriptional activities among different papillomavirus long control regions and their regulation by E2. Virology (2009) 0.79
Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers (Basel) (2014) 0.79
HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer (2012) 0.79
Human papillomavirus infections: warts or cancer? Cold Spring Harb Perspect Biol (2013) 0.78
Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. BMC Infect Dis (2014) 0.78
IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review). Oncol Rep (2014) 0.78
Stranglehold on the spindle assembly checkpoint: the human papillomavirus E2 protein provokes BUBR1-dependent aneuploidy. Cell Cycle (2015) 0.77
Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis (2015) 0.76
Diagnosis of 25 genotypes of human papillomaviruses for their physical statuses in cervical precancerous/cancerous lesions: a comparison of E2/E6E7 ratio-based vs. multiple E1-L1/E6E7 ratio-based detection techniques. J Transl Med (2014) 0.75
Mate-Pair Sequencing as a Powerful Clinical Tool for the Characterization of Cancers with a DNA Viral Etiology. Viruses (2015) 0.75
Molecular mechanisms of HPV mediated neoplastic progression. Infect Agent Cancer (2016) 0.75
Integration of human papillomavirus type 16 in cervical cancer cells. Open Med (Wars) (2014) 0.75
Viral E6 is overexpressed via high viral load in invasive cervical cancer with episomal HPV16. BMC Cancer (2017) 0.75
RNA extraction method is crucial for human papillomavirus E6/E7 oncogenes detection. Virol J (2017) 0.75
Increased methylation of human papillomavirus type 16 DNA is associated with the severity of cervical lesions in infected females from northeast China. Oncol Lett (2017) 0.75
Different Association of Human Papillomavirus 16 Variants with Early and Late Presentation of Cervical Cancer. PLoS One (2016) 0.75
Oral HPV prevalence in women positive for cervical HPV infection and their sexual partners: a German screening study. Eur Arch Otorhinolaryngol (2016) 0.75
Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. Microbes Infect (2017) 0.75
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol (2008) 3.75
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29
Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res (2004) 2.24
Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2008) 2.12
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12
Clinical relevance of objectifying colposcopy. Arch Gynecol Obstet (2014) 2.03
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
From human papillomavirus to cervical cancer. Obstet Gynecol (2010) 1.89
Evaluation of the VITOM in digital high-definition video exocolposcopy. J Low Genit Tract Dis (2011) 1.87
Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet (2011) 1.84
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol (2012) 1.78
A new approach to preserve fertility by using a coated nitinol stent in a patient with recurrent cervical stenosis. Fertil Steril (2006) 1.78
Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol (2008) 1.77
A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother (2009) 1.75
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis (2015) 1.73
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Laparoscopic-assisted radical vaginal hysterectomy (LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol (2003) 1.70
Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy? Gynecol Oncol (2005) 1.68
Lineage specification of parietal epithelial cells requires β-catenin/Wnt signaling. J Am Soc Nephrol (2011) 1.64
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis. Cancer Cytopathol (2012) 1.60
Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev (2013) 1.58
Biomarkers in cervical cancer screening. Dis Markers (2007) 1.58
Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst (2005) 1.55
Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol (2009) 1.54
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer (2005) 1.48
New paradigm for prevention of cervical cancer. Eur J Obstet Gynecol Reprod Biol (2006) 1.48
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol (2009) 1.48
An in vivo and in vitro model of Plasmodium falciparum rosetting and autoagglutination mediated by varO, a group A var gene encoding a frequent serotype. Infect Immun (2008) 1.45
Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer (2012) 1.44
Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer (2006) 1.44
Non-random integration of the HPV genome in cervical cancer. PLoS One (2012) 1.43
A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene (2003) 1.42
Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.42
Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res (2003) 1.42
Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev (2005) 1.42
Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer (2014) 1.41
Detection of hematogenous tumor cell dissemination predicts tumor relapse in patients undergoing surgical resection of colorectal liver metastases. Ann Surg (2005) 1.41
Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst (2012) 1.40
Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer (2004) 1.40
Cyclodimerization of an oxoboryl complex induced by trans ligand abstraction. Angew Chem Int Ed Engl (2010) 1.39
The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy. J Low Genit Tract Dis (2015) 1.39
Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst (2013) 1.38
How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine (2008) 1.35
Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer (2005) 1.35
Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J Minim Invasive Gynecol (2005) 1.32
The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res (2008) 1.30
Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer (2011) 1.30
A palindrome-mediated recurrent translocation with 3:1 meiotic nondisjunction: the t(8;22)(q24.13;q11.21). Am J Hum Genet (2010) 1.30
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol (2015) 1.30
Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer (2008) 1.29
Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev (2008) 1.29
New technologies and procedures for cervical cancer screening. Vaccine (2012) 1.29
Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene (2002) 1.28
Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR Am J Roentgenol (2005) 1.27
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol (2006) 1.26
Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene (2005) 1.26
Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol (2011) 1.25
Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res (2005) 1.25
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. Int J Cancer (2012) 1.21